Insider buying last 90 days
No open-market insider purchases were filed for HUM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every HUM insider filing, plotted on the chart in Gekko.Open HUM in Gekko
NYSE: HUM
Humana (HUM) Stock Analysis & Forecast
$386.22+1.70 (+0.4%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryHumana trades at $386.22, up 0.4%, sitting between its 50-day average of $388.65 and 200-day average of $287.02. The GekkoIndex reads 60, placing HUM in the Accumulation zone, up 9.2 over five days. Shares stand 24.5% below Gekko Fair Value of $511.86. Over the past year the stock has returned 43.4%, with a six-month gain of 132% and a three-month gain of 7.1%.
Recent activity centers on analyst and institutional positioning. Wall Street Zen upgraded HUM to "Buy" from "Hold," while the broader consensus target sits at $403.91 according to that report. Several institutional filings show mixed moves: Corient Private Wealth LP cut its stake by 15.3%, National Pension Service trimmed its position by 3.5% to 178,391 shares worth $70.86 million, while Bank of America Corp DE built a new stake of 703,615 shares valued at approximately $279.49 million, and Baird Financial Group and Manufacturers Life Insurance Company each added to existing holdings. Separately, Humana published research linking pharmacy care coordination to improved outcomes for cancer patients, and highlighted its Community Day initiative, which generated 2.2 million meals nationwide.
Looking ahead, Humana's next earnings date falls on 6 November, 47 days out and beyond a typical 20-trading-day window. In the last 30 days, three unusual options signals appeared, with put premium of $8,380,075 against zero call premium. Seasonally, the next 20 trading days have averaged a 1.5% gain over five years, positive in 3 of those years. Analyst coverage stands at 23 firms, 11 rating HUM a buy, 11 hold, and 1 sell, with a consensus target of $419.04.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $386.22200-day averageGekko Fair Value $511.86
Key stats
- Market cap
- $46.35B
- P/E ratio
- 36.4
- Forward P/E
- 25
- EPS, TTM
- $10.57
- Revenue, TTM
- $145.7B
- Profit margin
- 0.9%
- Dividend yield
- 0.92%
- Beta
- 0.75
- Volume
- 1.68M avg 963,529
- 1-year return
- +43.4%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±6.3%
- 50-day average
- $388.65
- 200-day average
- $287.02
- Next earnings
- Nov 6 before open
- Shares outstanding
- 120.1M
Humana swing-trade checklist
Humana scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $386.22 sits between the 50-day ($388.65) and 200-day ($287.02) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60, Accumulation
Reading 60 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
24.5% below
Price is 24.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 3 unusual options signals.
See smart money - Earnings risksupportive
Reports in 47 days
Next report Nov 6, 2026, 47 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.5% on average
From this point in the calendar, the next 20 trading days averaged +1.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Humana stock chart and price history
Humana closed at $386.22 on Sep 18, 2026, +43.4% over the past year, inside a 52-week range of $163.11 to $428.88.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.2%
- 3 months
- +7.1%
- 6 months
- +132.0%
- 1 year
- +43.4%
The full HUM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HUM in Gekko
Follow Humana through every session
Put HUM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track HUM in GekkoFree for 7 days. No credit card required.
About Humana
Humana provides health insurance and related benefits to individuals and groups throughout the United States, working through a network of subsidiary companies. It is known for offering medical coverage alongside supplemental products such as dental, vision, and other ancillary plans, serving consumers directly as well as employer groups.
The company organizes its work into three segments: Retail, Group and Specialty, and Healthcare Services. It contracts with government bodies, including an agreement with the Centers for Medicare and Medicaid Services to run the Limited Income Newly Eligible Transition prescription drug program, and it partners with various states to provide Medicaid, dual-eligible, and long-term care benefits. For employers, Humana offers fully insured commercial health coverage and administrative-services-only arrangements, and it supports military members through contracts such as TRICARE T2017 East Region. Its Healthcare Services segment extends beyond insurance into pharmacy management, provider network operations, and home-based care, serving both its own plan members and outside clients.
Humana is headquartered in Louisville, Kentucky, and was founded in 1961. Its shares are listed on the NYSE under the ticker HUM.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Managed health care
- Website
- humana.com
Humana GekkoIndex: the smart money zone
Humana’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60, in the Accumulation zone, up 9.2 points over five sessions.
60Accumulation
Up 9.2 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 74 | −0.3% | −1.0% | ||
| Accumulation (current zone) | 228 | +0.5% | +3.6% | ||
| Neutral | 309 | 0.0% | −1.3% | ||
| Distribution | 49 | +1.5% | +8.5% | ||
| Selling | 2 | Too few readings yet | |||
Average HUM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the HUM price, zone by zone.Track HUM in Gekko
Is Humana stock overvalued? Gekko Fair Value
Humana trades 24.5% below Gekko Fair Value of $511.86, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Humana shares are worth, recalculated every trading day.
$511.86
Gekko Fair Value, Sep 19, 2026
24.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open HUM in Gekko
Humana insider and Congress trading
No open-market insider purchases were filed for Humana, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in HUM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for HUM, plotted on the chart in Gekko.Open HUM in Gekko
Buybacks
Humana has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.00M
- As a share of market cap
- 0.00%
From company filings.
Unusual options activity last 30 days
3signals, 0% of the flagged premium in calls.
Latest: Bearish flow on Sep 15, $3.54M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold HUM.
1added0opened1trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Humana earnings: next date and track record
Humana reports on Nov 6, 2026, before the open (47 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 6, 2026
Expected before the open, 47 days away
- EPS estimate
- −$1.00
- Revenue estimate
- $40.87B
6 of 8reports beat the EPS estimate
±4.7%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Apr 29, 2026 AI summary
- What they said
- Humana reported a first quarter consistent with expectations and reiterated its Investor Day commitments, including a target to return to a sustainable Medicare Advantage margin of at least 3% in 2028 with progress in 2027. Management described member growth as on track, early indicators (risk scores, hospital admits per thousand, pharmacy claims, initial medical claims) as in line to better than guidance, and emphasized enhanced claims monitoring and payment-integrity efforts. They noted continued CenterWell growth across pharmacy, primary care, and home health but some one-time/timing items in Q1 that will normalize through the year. Management discussed balance-sheet optimization actions (including $1B junior subordinated notes, subsidiary reinsurance, legal entity changes), maintaining dividends while limiting buybacks until cash flows improve, and pursuing noncore asset divestitures. Bidding strategy for 2027 will prioritize getting on track for the 2028 margin goal, member retention, and disciplined market-by-market adjustments; management acknowledged that medical cost trend continues to outpace program funding and that benefit adjustments will be used where necessary. They also described operational and cost efficiency efforts via a transformation office, tactical and strategic cost reductions, outsourcing optimization, and claims-reserve prudence. During Q&A, management reiterated confidence in underlying trends while acknowledging remaining funding gaps, potential cash obligations related to put/call options with Welsh Carson (approx. $1.0–$1.5B in 2027 if exercised), and near-term OCR noise in CenterWell that should normalize.
- Guidance
- Management reaffirmed prior-year guidance and reiterated the Investor Day targets: return to a sustainable Medicare Advantage margin of at least 3% in 2028 and make progress in 2027. They are maintaining 2026 guidance and continue to take a prudent reserving posture. They noted Q2 MLR guidance slightly above ~91% and that any potential outflows related to Welsh Carson put/call options have been included in their funding plan. No specific numeric revenue or EPS mid-year targets were provided beyond these directional and target-margin commitments.
- Risks flagged
- Medical cost trend continues to outpace program funding, creating funding shortfalls that may require benefit reductions and geographic/market adjustments. Reserve and claims uncertainty early in the year (IBNR growth) requires prudent reserving. Potential cash obligations tied to Welsh Carson put options (~$1.0–$1.5B in 2027 if exercised). OCR/earnings noise in CenterWell driven by one-time items and acquisition timing. Regulatory and programmatic constraints (TBC limits, Stars/quality score impacts) could constrain bidding flexibility. Macroeconomic and weather-related variability and ongoing execution risk in integrations and cost transformation initiatives.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 29, 2026 | $10.31 est $10.20 | $39.65B est $39.37B | +2.9% |
| Feb 11, 2026 | −$3.96 est −$4.00 | $32.52B est $32.04B | −1.4% |
| Nov 5, 2025 | $3.24 est $2.93 | $32.65B est $32.00B | −10.9% |
| Jul 30, 2025 | $6.27 est $5.87 | $32.39B est $31.87B | +7.4% |
| Apr 30, 2025 | $11.58 est $10.07 | $32.11B est $32.20B | −1.3% |
| Feb 11, 2025 | −$2.16 est −$2.12 | $29.21B est $28.81B | −2.5% |
| Oct 30, 2024 | $4.16 est $3.39 | $29.40B est $28.68B | 0.0% |
| Jul 31, 2024 | $5.62 est $5.62 | $29.54B est $28.52B | −11.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Humana stock forecast and analyst price targets
Analysts’ average 12-month price target for Humana is $419.04, +8.5% from the last close, from 23 firms rating the stock in the last 90 days.
$419.04consensus 12-month target, +8.5% from the last close
Now $386.22Avg $419.04
Low $280High $624
Each firm’s latest rating in the last 90 days: 23 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | Wells Fargo | $502 | +30.0% |
| Sep 10 | Barclays | $407 | +5.4% |
| Sep 9 | Bernstein | $425 | +10.0% |
| Sep 8 | Bank of America Securities | — | — |
| Sep 4 | Bernstein | $425 | +10.0% |
+3.6%average 20-day move after past Accumulation readings
+1.5%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Humana seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Humana averaged +1.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 2 of 5 |
| Next 10 trading days | −2.3% | 2 of 5 |
| Next 15 trading days | −0.7% | 3 of 5 |
| Next 20 trading days | +1.5% | 3 of 5 |
| Next 30 trading days | +6.0% | 4 of 5 |
For scale, HUM’s typical 20-trading-day move in either direction is about 6.3%.
Humana market cap and key statistics
Humana’s market cap is $46.35B, with a P/E ratio of 36.4 and revenue of $145.7B over the last twelve months.
Valuation
- Market cap
- $46.35B
- P/E ratio
- 36.4
- Forward P/E
- 25
- EPS, TTM
- $10.57
- Gekko Fair Value
- $511.86
Trading
- Volume
- 1.68M
- Avg volume, 20 days
- 963,529
- 52-week high
- $428.88
- 52-week low
- $163.11
- Shares outstanding
- 120.1M
Financials
- Revenue, TTM
- $145.7B
- Profit margin
- 0.9%
- Return on equity
- 6.9%
- Quarterly earnings growth, YoY
- +27.1%
Risk and income
- Beta
- 0.75
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±6.3%
- Dividend yield
- 0.92%
Humana stock news this week
Coverage of Humana this week reads positive: 4 positive, 3 neutral and 0 negative headlines.
- Humana (NYSE:HUM) Upgraded to "Buy" at Wall Street ZenMarketBeat, Sep 19
- Corient Private Wealth LP Cuts Stake in Humana Inc. $HUMDefense World, Sep 18
- New Humana research finds association between pharmacy care coordination services and improved health outcomes for cancer patientsBusiness Wire, Sep 17
- Bank of America Corp DE Invests $279.49 Million in Humana Inc. $HUMMarketBeat, Sep 17
- Humana Community Day 2026 Generates 2.2 Million Meals and Community Investments NationwideGuruFocus, Sep 16
- Baird Financial Group Inc. Purchases 4,129 Shares of Humana Inc. $HUMMarketBeat, Sep 16
Humana peers
Humana’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| UNHUnitedHealth | Accumulation | 0.2% below |
| ELVElevance Health | Neutral | 33.5% below |
| CICigna | Accumulation | 37.8% below |
| CNCCentene | Neutral | 23.2% below |
| MOHMolina Healthcare | Neutral | 40.3% below |
| OSCROscar Health | Neutral | 0.5% below |
A peer links to its own page where one exists.
Humana stock FAQ
What is Humana’s market cap?
Humana’s market cap is $46.35B at the Sep 18, 2026 close of $386.22, with 120.1M shares outstanding. The shares trade on a P/E ratio of 36.4.
What is the Humana stock forecast?
The consensus analyst 12-month price target for Humana is $419.04, +8.5% from the last close. Of the 23 firms that rated the stock in the last 90 days, 11 rate it a buy, 11 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Humana stock overvalued or undervalued?
On Gekko’s estimate Humana is undervalued: the Sep 18, 2026 close of $386.22 is 24.5% below Gekko Fair Value of $511.86. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Humana report earnings next?
Humana is expected to report on Nov 6, 2026, before the market opens (47 days away). Analysts expect earnings of −$1.00 per share on revenue of $40.87B. Humana beat the earnings estimate in 6 of its last 8 reports, moving 4.7% on average across the report.
What is Humana’s 52-week high and low?
Humana’s 52-week high is $428.88 and its 52-week low is $163.11; it closed at $386.22 on Sep 18, 2026, +43.4% over the past year.
Is Humana stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Humana?
Gekko flagged 3 unusual options signals in Humana over the last 30 days, with $0 of flagged premium in calls and $8.38M in puts. The latest, bearish flow, was on Sep 15, 2026 with $3.54M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Humana the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.